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Jose´ J. Fuster, Vicente Andre´s
Abstract—Accumulation of cellular damage with advancing age leads to atherothrombosis and associated cardiovascular
disease. Ageing is also characterized by shortening of the DNA component of telomeres, the specialized genetic
segments located at the end of eukaryotic chromosomes that protect them from end-to-end fusions. By inducing genomic
instability, replicative senescence and apoptosis, shortening of the telomeric DNA is thought to contribute to organismal
ageing. In this Review, we discuss experimental and human studies that have linked telomeres and associated proteins
to several factors which influence cardiovascular risk (eg, estrogens, oxidative stress, hypertension, diabetes, and
psychological stress), as well as to neovascularization and the pathogenesis of atherosclerosis and heart disease. Two
chief questions that remain unanswered are whether telomere shortening is cause or consequence of cardiovascular
disease, and whether therapies targeting the telomere may find application in treating these disorders (eg, cell
“telomerization” to engineer blood vessels of clinical value for bypass surgery, and to facilitate cell-based myocardial
regeneration strategies). Given that most research to date has focused on the role of telomerase, it is also of up most
importance to investigate whether alterations in additional telomere-associated proteins may contribute to the
pathogenesis of cardiovascular disease. (Circ Res. 2006;99:1167-1180.)
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 estrogens
Telomeres are special chromatin structures located at theends of eukaryotic chromosomes that prevent the recog-
nition of chromosomal ends as double-stranded DNA breaks,
thereby protecting these regions from recombination and
degradation and avoiding a DNA damage cellular response.
The telomeric DNA is composed of noncoding double-
stranded repeats of G-rich tandem DNA sequences
(TTAGGG in vertebrates) that are extended several thousand
base pairs (10 to 15 kb in humans and 25 to 40 kb in mice)
and end in a 150 to 200 nucleotide 3 single-stranded
overhang (G-strand overhang) (Figure 1).1,2 Several specific
proteins are associated to telomeric DNA, including telom-
erase and the telomeric repeat binding factors 1 and 2 (TRF1,
TRF2) which directly bind to the TTAGGG repeat and
interact with other factors forming large protein complexes
that regulate telomere length and structure. Mammalian
telomerase consists of a RNA component (telomerase RNA
component [TERC]) that serves as a template for the synthe-
sis of new telomeric TTAGGG repeats by the telomerase
reverse transcriptase component (TERT). Telomere compo-
nents and structure has been comprehensively discussed
elsewhere.2
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Although telomerase expression is constitutive in most
unicellular organisms, mammalian adult somatic cells typi-
cally exhibit low or absent telomerase activity and thus
display progressive telomere attrition with each mitotic cycle
(the so-called “end replication problem” caused by the
incomplete replication of linear chromosomes by conven-
tional DNA polymerases) (Figure 2). Accordingly, telomere
length in somatic cells reflects their replicative history and
can predict their remaining proliferative potential. Cells with
critically short telomeres undergo chromosomal end-to-end
fusions, replicative senescence, and apoptosis. In contrast to
somatic cells, germ, stem, and tumor cells as well as immor-
talized cell lines maintain high levels of telomerase activity
and thus display longer telomeres and maintain a relatively
high proliferative potential (Figure 2).3–6 Remarkably, TERT
gene transfer reduces replicative senescence and extends the
lifespan of numerous cell types, including cardiac myocytes,
vascular smooth muscle cells (VSMCs), and endothelial cells
(ECs) (Table 1). Telomerase-dependent transcriptional regu-
lation of genes involved in cell growth has been recently
suggested as an additional mechanism by which telomerase
promotes cell proliferation independently of telomere length
maintenance.7
Telomerase expression and activity and telomere length are
developmentally regulated, with generally greater telomerase
activity during embryonic development and low or undetect-
able levels soon after birth.5,8,9 Human telomerase activity
(hTERT) remains detectable in adult cell populations with
high proliferative potential, such as activated lymphocytes
and certain types of stem cells.10–12 Moreover, there is also an
important body of evidence demonstrating the occurrence of
tissue-specific regulation of telomerase activity, both during
embryonic development and in adulthood.5,9,13–15 Alterna-
tively spliced human TERT (hTERT) transcripts have been
detected in several adult normal and tumor tissues and their
expression that has been shown to be regulated in a tissue-
specific manner during development.16–20 This often leads to
the expression of hTERT isoforms lacking functional reverse
transcriptase domains, including dominant negative inhibitors
of telomerase activity (eg, hTERT).17,18
Telomere length is highly variable among individuals of
the same age, both in rodents5,8 and humans.21–25 Studies in
twins suggest that this interindividual variability may be
accounted for by genetic factors,22,24 and Nawrot et al
concluded that inheritance of telomere length is linked to X
Figure 1. Telomere organization. Telo-
meres are specialized nucleoprotein
structures located at the end of eukary-
otic chromosomes that protect them
from end-to-end fusions, thus preserving
genome integrity and stability. The syn-
thesis of new telomeric DNA repeats in
dividing cells requires the activity of
telomerase and additional telomere-
associated proteins. Telomerase has a
catalytic subunit (telomerase reverse
transcriptase [TERT]) and an RNA com-
ponent (telomerase RNA component
[TERC]) that serve as a template for de
novo synthesis of telomeric DNA. TRF1/2
indicates telomeric repeat binding fac-
tor1/2; POT1, protection of telomeres 1;
TANK1/2, tankyrase 1/2; TIN2, TRF1-
interacting nuclear factor 2; TERF2IP,
TRF2-interacting telomeric RAP1 protein;
NBS1, Nijmegen breakage syndrome 1
protein (Nibrin); MRE11, meiotic recom-
bination 11; Ku86, Ku autoantigen, 86
kDa; DNA-PKcs, DNA-activated protein
kinase catalytic subunit.
Figure 2. Telomerase regulation, telomere
dynamics, and cellular homeostasis. Most
adult somatic cells have low or absent
telomerase activity; hence they experience
progressive telomere ablation with each
mitotic cycle during normal aging and pas-
sage in culture. Once telomeres become
critically short, cells accumulate chromo-
somal aberrations, become senescent, and
eventually undergo apoptosis. Prolonged
lifespan and proliferative capacity of germ,
stem, immortalized, and tumor cells corre-
lates with high telomerase activity. Several
human premature aging syndromes (eg,
Werner syndrome, ataxia telangiectasia, dys-
keratosis congenita) are characterized by
accelerated telomere exhaustion.
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chromosome.26 However, the influence of environmental
factors on the rate of telomere attrition may also be of great
importance in determining telomere length in adulthood. For
example, whereas Okuda et al reported no differences in
telomere length in several human tissues when comparing
male and female newborns,21 studies with humans and
rodents have revealed higher telomerase activity27 and longer
telomeres8,9,28 in females compared with males in various
adult tissues. As discussed below, estrogen-dependent acti-
vation of telomerase may contribute to these gender-related
differences in telomere length that arise during adulthood.
Furthermore, prospective epidemiological studies have re-
vealed higher telomere attrition rates in white blood cells
(WBCs) of diabetic and obese human subjects29 (see below).
The consequences of telomere ablation at the organismal
level have been rigorously assessed in TERC-deficient
mice,30–38 which undergo progressive telomere shortening
with each generation and lose viability when they reach
critically short telomeres (typically after 3 to 5 generations).
Remarkably, late generation TERC-null mice display prema-
ture aging symptoms and associated disorders, such as
infertility, hair graying, alopecia, heart dysfunction, hyper-
tension, various tissue atrophies and decreased tissue regen-
eration capacity.30–36,38 These findings indicate that a mini-
mal telomere length is required to maintain tissue
homeostasis in the mouse and lend support to the notion that
progressive telomere shortening may be involved in the
pathogenesis of age-related human disorders. Accordingly,
telomerase activity is impaired, or telomere attrition is accel-
erated, in various human premature aging syndromes, such as
dyskeratosis congenita,39 Werner syndrome,40 or ataxia tel-
angiectasia.41 Remarkably, ectopic expression of telomerase
rescues telomere defects in cells from patients experiencing
dyskeratosis congenita thus supporting the importance of
telomerase deficiency in the pathology of this disease.42
Because aging is a major cardiovascular risk factor,43,44
addressing whether age-dependent telomere exhaustion af-
fects cardiovascular pathobiology has been the center of
intensive research in recent years. In the next sections, we
discuss the results and main conclusions that have arisen from
experimental and human studies that have linked telomere
function to neovascularization and the development of ath-
erosclerosis and heart disease, as well as to several factors
known to influence cardiovascular risk, such as estrogens,
oxidative stress, hypertension, diabetes, psychological stress,
and smoking. We also discuss the potential use of “telomer-
ization” strategies for cardiovascular therapy.
TABLE 1. Cell Culture Studies Implicating Telomere Length and Telomerase in Cardiovascular Pathobiology
Cell Type Main Findings References
Vascular smooth muscle cells Increased telomerase activity correlates with VSMC proliferation 60, 63
Hypoxia induces telomerase activity and cell proliferation in human VSMCs 59
Telomerase inhibition rapidly abrogates VSMC proliferation 60, 61, 63
hTERT-forced overexpression extends the lifespan of VSMCs 58, 80
hTERT expression rescues the senescent phenotype of human plaque VSMCs despite
short telomeres
62
Oxidative stress inhibits telomerase activity and accelerates telomere shortening in VSMCs 62
Endothelial cells Telomere attrition correlates with limited proliferative capacity of passaged human ECs 50, 149
Telomerase ectopic overexpression augments the lifespan of human ECs 52, 80, 150
Constitutive hTERT expression enhances the regenerative capacity of endothelial progenitor cells 89
Fibroblast growth factor-2, but not vascular endothelial growth factor, upregulates telomerase
activity and delays the onset of senescence in HUVECs
151, 152
Estrogen induces telomerase activity by activating the phosphatidylinositol 3-kinase/Akt pathway
and stimulating nitric oxide production in ECs and other cell types
118–122
Oxidized LDLs diminish Akt and telomerase activity in ECs 126
Chronic mild oxidative stress downregulates telomerase and accelerates telomere erosion and the
onset of senescence in human ECs
127
Statins upregulate TRF2 by a post-transcriptional mechanism and enhance the migratory capacity
of endothelial progenitor cells via a TRF2-dependent mechanism
153
Homocysteine increases the rate of telomere shortening in ECs and this effect is attenuated by
catalase treatment
130
Antioxidants prevent TERT nuclear export and downregulation of telomerase activity and delay
replicative senescence of human ECs
134
Aspirin prevents the increase in ROS formation and telomerase downregulation occurring during
endothelial senescence
138
Cardiac myocytes Overexpression of hTERT induces hypertrophy and inhibits apoptosis 94
TRF2 inactivation causes telomere erosion, Chk2 activation, and increases apoptosis in cultured
rat ventricular myocytes
95
Short telomeres in late generation TERC-null mice upregulate the tumor suppressor protein p53
in cardiomyocytes
35
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Telomeres and Atherosclerosis
Atherosclerosis is a complex inflammatory process that
involves both adaptive and innate immune mechanisms.43–48
EC dysfunction triggered by atherogenic stimuli (eg, elevated
plasma cholesterol level, hypertension, diabetes, and smok-
ing) is of central importance in the pathogenesis of athero-
sclerosis. Table 1 summarizes the results of in vitro studies
implicating telomeres and telomerase in EC function. In vivo,
age-dependent telomere shortening has been reported in ECs
from iliac, thoracic, and coronary arteries49–51 (Figure 3).
Minamino et al reported that vascular ECs with senescence-
associated phenotypes are present in human atherosclerotic
lesions.52 Notably, a dominant-negative TRF2 mutant that
destroys telomere structure53,54 induces, when ectopically
overexpressed in human ECs, a senescent phenotype as well
as functional alterations involved in atherogenesis, such as
increased expression of intercellular adhesion molecule 1
(ICAM-1) and diminished endothelial nitric oxide synthase
(eNOS) activity.52 Conversely, transduction of TERT inhib-
ited both EC senescence and associated functional alter-
ations.52 Notably, Ogami et al found shorter telomeres in
coronary ECs of patients with coronary artery disease (CAD)
than in age-matched non-CAD patients, and in atherosclerotic
coronary ECs compared with those at nonatherosclerotic sites
in 6 individual CAD patients.51 Collectively, these studies
suggest that EC dysfunction and replicative senescence in-
duced by telomere shortening play a critical role in coronary
atherogenesis.
Once fatty streaks are formed, activated neointimal leuko-
cytes produce a plethora of inflammatory mediators that
contribute to atheroma growth by provoking excessive
VSMC proliferation and migration.43,44,55–57 Telomerase has
been implicated as an important regulator of VSMC prolif-
eration in vitro (Table 1), because TERT activation extends
the lifespan of cultured VSMCs and, conversely, telomerase
inhibition abrogates VSMC proliferation in a dose-dependent
manner.58–60 Regulation of VSMC proliferation by targeting
telomerase activity appears to be independent of telomere
length, because VSMC growth arrest occurs early after
telomerase inhibition60,61 and telomerase expression alone is
capable of rescuing the senescent phenotype of human plaque
VSMCs despite short telomeres.62
A role of telomerase on the control of VSMC growth has
been also proposed in vivo. Telomerase activation and
telomere maintenance appear to be critical for increased
VSMC hyperplastic growth in hypertensive rats.63 Further-
more, Ogawa et al found that telomerase activity and VSMC
hyperplasia are concomitantly induced in murine femoral
artery after endovascular artery denudation,61 and Gupta et al
reported a strong trend toward an association between telom-
erase activity and human restenosis,64 which is also charac-
terized by excessive VSMC proliferation.55,57 Likewise, te-
lomerase activity has been detected in 35% and 70% of
human atherosclerotic coronary artery specimens retrieved by
directional atherectomy64 or obtained from heart transplant
recipients,65 respectively. Whereas hTERT immunoreactivity
was faint or undetectable in 11 (85%) of 13 coronary arteries
without morphological abnormalities (Stage 0/I/II/III), strong
hTERT expression was detected in 14 (88%) of 16 coronary
segments with atheromas grading IV to VI confined to the
cell-rich area in the early thickened media/neointima or late
advanced lesions with severe calcification and necrosis.65
Notably, the frequency of hTERT immunoreactivity directly
correlated with relative telomerase activity. In a recent study,
Matthews et al found low levels of telomerase activity in
plaque VSMCs and shorter telomeres in coronary plaques
than in normal vessels from the same patients.62 These
authors identified fibrous cap VSMCs, which are a hallmark
of advanced plaques, as the main neointimal cell type
experiencing telomere attrition. Human plaque VSMCs
within the fibrous cap exhibited a senescent phenotype and
enhanced telomere loss compared with medial VSMCs or
non-VSMCs of the same lesion. VSMC senescence was
associated with changes in key cell cycle regulatory proteins
(eg, cyclins D/E, p16, p21, and pRB), and telomerase expres-
sion alone rescued plaque VSMC senescence despite short
telomeres, normalizing the changes in p16, p21, and pRB
protein expression.
Based on the aforementioned observations, the emerging
picture is that arterial cell hyperplastic growth at early stages
of atherosclerosis may be facilitated by telomerase activation.
Progressive telomere exhaustion in more advanced plaques,
possibly caused by multiple population doublings in the
presence of scarce or absent telomerase activity, may lead to
the accumulation of senescent ECs and VSMCs. Possible
factors causing telomerase inhibition and accelerated telo-
mere shortening include oxidative stress, hypertension, and
diabetes (see below). Enhanced EC turnover caused by
hemodynamic stress may contribute to telomere ablation in
this cell type, because age-dependent telomere shortening is
more prominent in atherosclerosis-prone vessels subjected to
high hemodynamic stress.50,66
Figure 3. Associations between athero-
sclerosis and telomere exhaustion in dif-
ferent tissues and cell types from
humans and TERC-null mice. Reference
nos. are shown.
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EC dysfunction in atherosclerotic vessels promotes the
adhesion and transendothelial migration of circulating leuko-
cytes. Several studies have established an association be-
tween telomere length in WBCs and atherosclerosis. Patients
with vascular dementia, a disorder that is frequently associ-
ated with cerebrovascular atherosclerosis and stroke, exhibit
significantly shorter WBC telomeres compared with age-
matched controls, namely cognitively competent patients
experiencing from cerebrovascular or cardiovascular disease
(CVD) alone, patients with probable Alzheimer’s dementia,
and apparently healthy individuals.67 Likewise, after adjust-
ment for age and sex, average telomere length in leukocytes
of 10 patients with severe CAD (age 42 to 72 years) was
significantly shorter compared with 20 controls with normal
coronary angiograms (age 39 to 72 years).68 Although anal-
ysis of 163 treated hypertensive men also revealed shorter
WBC telomeres in subjects with carotid artery plaques versus
subjects without plaques,69 Kurz et al have reported that
calcific aortic valve stenosis, but not CAD, is associated with
shorter leukocyte telomeres in a cohort of 193 elderly patients
(70 years of age).70
Matsubara et al investigated whether the (1327)T/C
polymorphism within the hTERT gene affects promoter
activity and leukocyte telomere length in normal individu-
als.71 Activity of the hTERT promoter was significantly lower
when the (1327)C-sequence was present. Moreover, age-
related telomere shortening was only clear in the (1327)C-
allele carriers, and telomeres were significantly longer in the
(1327)T-allele carriers. In a recent case-control study with
104 CAD patients and 115 age- and sex-matched controls, the
same investigators found shorter WBC telomere length and a
higher frequency of the hTERT (1327)C/C genotype
among cases compared with controls.72
Myocardial infarction (MI) is frequently a complication of
CAD patients. In a study comparing 203 cases with a
premature MI (50 years of age) and 180 controls, a
significant association between shorter WBC telomere length
and the risk of premature MI was detected after adjustment
for age and sex.73 Notably, subjects with shorter than average
telomeres had between 2.8- and 3.2-fold higher risk of MI
compared with subjects in the highest quartile for telomere
length.73 Moreover, analysis of 143 normal unrelated individ-
uals more than 60 years of age revealed an association
between shorter telomere length in blood DNA and poorer
survival that was partly attributed to a 3.18-fold mortality rate
from heart disease and a 8.54-fold higher mortality rate from
infectious disease.74 However, 2 recent studies suggest that
WBC telomere length is not associated with morbidity or
mortality in the oldest old.75,76 First, although Bischoff et al
observed in a cohort of 812 persons, aged 73 to 101 years, an
association between longer telomeres in blood cells and better
survival, no association was found when age was controlled
for in the analyses.75 Likewise, Martin-Ruiz et al concluded
that WBC telomere length is not a predictive indicator for
age-related morbidity and mortality at ages more than 85
years, possibly because of a high degree of telomere length
instability in this group.76
Certainly, additional epidemiologic studies are needed to
conclusively address if a link exists between leukocyte
telomere length and atherosclerosis in different vascular
regions, MI, and survival. Thus, it cannot be concluded at
present time that individuals with shorter telomeres might be
at higher risk of developing atherosclerosis. Indeed, because
excessive cell proliferation is a feature of atheroma develop-
ment and the rate of telomere shortening augments in most
somatic cells with increasing population doublings, an alter-
native explanation is that telomere ablation in WBCs and
arterial tissue from patients with atherosclerosis is a mere
consequence of increased cell turnover induced by the under-
lying chronic inflammatory response. To obtain further in-
sight into this question, we investigated the impact of telo-
mere exhaustion on diet-induced atherosclerosis in
apolipoprotein E (apoE)-null mice, a well-established model
of experimental atherosclerosis that recapitulates important
aspects of the human disease.77 We found that fourth gener-
ation mice doubly deficient in apoE and TERC (G4apoE-
TERC-DKO) had shorter telomeres and were protected from
aortic atherosclerosis compared with apoE-null mice with an
intact TERC gene.37 Remarkably, mitogen-induced prolifer-
ation was completely blunted in primary cultures of lympho-
cytes and macrophages obtained from G4apoE-TERC-DKO
mice, suggesting that immunoreplicative senescence may be a
mechanism by which telomere exhaustion protects from
atheroma growth in this experimental model. It remains
unresolved whether diminished VSMC proliferation may also
contribute to reduced neointimal thickening in fat-fed
G4apoE-TERC-DKO mice. Likewise, examination of appro-
priate animal models is needed to ascertain whether telomere
attrition, by inducing VSMC senescence or apoptosis, may
promote plaque rupture and thrombus formation.
Because human aging is associated with telomere erosion
in most somatic cells,78 the higher prevalence of atheroscle-
rosis within the elderly appears to challenge the finding made
in mice that short telomeres protect from atherosclerosis.
Although profound differences in telomere biology between
humans and rodents cannot be discarded, these seemingly
conflicting findings might be reconciled if accepting that
accumulation of cellular damage imposed by prolonged
exposure to cardiovascular risk factors ultimately prevails
over protective mechanisms, including telomere exhaustion.
Consistent with this notion, diet-induced atherosclerosis was
significantly reduced in old compared with young rabbits.79 A
definitive answer to the question of whether telomere ablation
is a primary cause or a consequence of atherosclerosis
requires prospective epidemiological studies to ascertain
whether telomere length in newborns is a predictor of
atherosclerosis and associated CVD in adulthood indepen-
dently of well-established cardiovascular risk factors. In
addition, large prospective epidemiological studies are
needed to ascertain whether augmented rates of telomere
attrition in WBCs are associated with atherosclerosis progres-
sion and the influence on this parameter of major atherogenic
stimuli.
The limited replicative capacity of adult VSMCs may be a
rate-limiting step in engineering blood vessels of clinical
value for bypass surgery. Indeed, robust human vessels have
been engineered in vitro using hTERT-expressing VSMCs,
which proliferated far beyond their normal lifespan and
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retained phenotypic characteristics of normal VSMCs.58,80
Apart from this potential use in vessel engineering for revascu-
larization of ischemic tissues, it is still uncertain whether
additional telomerization strategies may some day be of clinical
application for patients with atherosclerotic disease. Indeed, a
chief question is establishing whether telomere lengthening or
exhaustion may be beneficial in these patients. On the one hand,
maintaining/restoring telomere length could prevent or amelio-
rate endothelial senescence/dysfunction and improve neovascu-
larization of ischemic territories (see next section). However,
long telomeres may accelerate atheroma progression by exacer-
bating neointimal leukocyte and VSMC proliferation. Of note in
this regard, reduced TERT activity appears required for the
antiproliferative effects that thiazolidinediones exert on
VSMCs,61 although it is unknown whether TERT inhibition by
these peroxisome proliferator-activated receptor- ligands used
as antidiabetic drugs in patients with type 2 diabetes is also
necessary for their antirestenotic effects in the vasculature.81
Telomeres and Neovascularization
The restoration of blood flow into ischemic regions in the
adult organism depends on de novo vessel formation by
endothelial progenitor cells (EPCs) (vasculogenesis) and on
the development of new collateral vessels from established
vascular networks (angiogenesis).82 On the other hand, an
important body of evidence implicates neointimal angiogen-
esis as a mechanism contributing to atheroma growth.83,84
TERC-null mice with critically short telomeres display a
marked reduction in angiogenesis in both Matrigel implants
and murine melanoma grafts, which was associated with
reduced and increased tumor cell proliferation and apoptosis,
respectively, as well as a lower tumor growth rate.34 Thus, it
is tempting to speculate that telomere exhaustion may con-
tribute to age-dependent impairment of angiogenesis.85 Fur-
ther evidence implicating telomerase as a key regulator of
neovascularization is provided by the observation that
hTERT mRNA expression in ECs of newly formed vessels
directly correlates with the histological grade of human
tumors.86 It will be of great interest to identify the diffusible
factor(s) produced by glioblastoma cells in vitro that upregu-
late hTERT mRNA and protein expression and telomerase
activity in ECs.87 The demonstration that hypoxia, a funda-
mental angiogenic stimulus, induces in VSMCs TERT pro-
tein expression and phosphorylation59 also highlights the
importance of telomerase for angiogenesis. Notably, overex-
pression of hTERT in human dermal microvascular ECs
augments their capacity to form more durable microvascular
structures when subcutaneously xenografted in severe com-
bined immunodeficiency mice.88 Likewise, hTERT gene
transfer improves the proliferative and migratory activity as
well as the survival of human EPCs and increases neovascu-
larization and limb salvage in a murine hindlimb ischemia
model.89 However, it is important to note that telomere-
independent barriers might limit the transplantation potential
of murine hematopoietic stem cells, because overexpression
of TERT in these cells did not extend transplantation capacity
in spite of preserving telomere loss during serial
transplantation.90
Telomeres and Heart Pathobiology
As in other adult tissues, telomerase activity in the adult heart
is markedly downregulated after birth and remains low or
absent through adulthood, both in rodents91–94 and in hu-
mans.14,16,95 It is widely accepted that most cardiac cells are
differentiated postmitotic myocytes, and it has been postu-
lated that restoring their proliferative capacity by increasing
telomerase activity may facilitate the regeneration of myo-
cardial tissue after MI or the restitution of chronic myocyte
loss in heart failure. Indeed, transgenic mice engineered to
express TERT specifically in cardiomyocytes maintain te-
lomerase activity and telomere length in the adult heart, and
this correlated with reduced area of MI, less fibrous area, and
preservation of systolic function after mechanical and ische-
mic injury (Figure 4).94,95 It is noteworthy that cardiac TERT
expression induced a biphasic response with decreased myo-
cyte size and increased cell density in the heart of 2-week-old
transgenic mice, and ventricular hypertrophy and increased
myocyte size at 12 weeks of age. Thus, cardiac-specific
TERT expression in the mouse may initially delay cardiac
myocyte cell cycle exit and subsequently induce late-onset
cell hypertrophy. However, primary cultures of postmitotic
Figure 4. Associations among heart dis-
ease, telomerase, and telomere length in
different tissues and cell types from
humans and genetically modified mice.
Reference nos. are shown.
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rat ventricular myocytes overexpressing TERT exhibited
hypertrophic growth but did not undergo DNA replication.94
Leri et al detected telomerase activity in pure preparations
of young adult, fully mature adult, and senescent rat ventric-
ular myocytes,27 in contrast to previous studies reporting lack
of telomerase activity in the adult heart.92 Because telomerase
activity is a characteristic of proliferating cells, these findings
were interpreted as an indication that replicative-competent
cardiac cells exist throughout life and that these cells may
counteract the continuous cell death in the aging mammalian
heart. Indeed, defeating the dogma that adult heart is a
terminally differentiated organ without self-renewal potential,
several reports have demonstrated the existence of a subpopu-
lation of replicating cardiomyocytes in normal and patholog-
ical states.96–100 Moreover, increasing evidence supports the
existence of telomerase-expressing multipotent cardiac stem
cells (CSCs), which contribute to myocardial regeneration in
the adult heart.101–104
Table 1 summarizes the results of in vitro studies impli-
cating telomeres and telomerase in cardiomyocyte function.
Several in vivo studies have investigated the role of telom-
erase and telomere length in the pathogenesis of heart disease
(Figure 4). As discussed above, reduced telomere length in
WBCs is associated with increased risk of MI and heart
disease and higher mortality rate.73,74 Telomere attrition in the
heart has also been detected in patients experiencing from
age-related cardiomyopathy (characterized by an increase of
cell senescence markers, moderate hypertrophy and cardiac
dilatation)105 and in patients with cardiac hypertrophy con-
secutive to aortic stenosis with a mean duration of 3 years,103
in spite of increased telomerase activity in the heart in both
cases. In contrast, in a dog model of acute heart failure with
progressive deterioration of cardiac performance and dilated
cardiomyopathy, telomerase activity increased during the
onset and progression of ventricular dysfunction and, in this
case, appeared sufficient to preserve telomere length.106
Notably, it has been suggested that telomere shortening
impairs CSC-mediated myocardial regeneration by limiting
the proliferative potential of these cells. Supporting this
notion, Urbanek et al found that telomerase-competent CSCs
increase in number immediately after MI, but this growth
response is attenuated in chronic heart failure concomitant
with decreased telomerase activity, severe telomeric shorten-
ing, and the accumulation of senescent cells.104
The examination of successive generations of TERC-null
mice additionally highlights the importance of telomere
attrition in cardiac pathology (Figure 4).35 Aged fifth-
generation TERC-deficient mice (G5TERC-KO) exhibited
significantly shorter telomeres in cardiomyocytes, ventricular
dilation, thinning of the myocardium, cardiac dysfunction,
and sudden death. Heart sections from G5TERC-KO mice
revealed increased level of expression of the tumor suppres-
sor protein p53, reduced proliferation, and increased apopto-
sis, as well as a 50% reduction in the number of left
ventricular myocytes compared with wild-type mice. Nota-
bly, p53 protein level and telomere exhaustion were corre-
lated in G5TERC-KO cardiomyocytes. The pathways con-
necting telomeres and p53 in senescence and apoptosis are
reviewed elsewhere.107
Apart from its possible role in establishing replicative
senescence of CSCs, telomere dysfunction may also contrib-
ute to heart disease by inducing apoptosis. Increased cell
death, frequently associated to decreased levels of the
telomere-associated protein TRF2, has been detected in
senescent cardiac cells with significant telomere shortening in
aged diseased hearts105 and in hearts of patients experiencing
from acute and chronic MI104 or heart failure.95 Remarkably,
apoptosis after ischemic (coronary ligation) and biomechani-
cal (partial occlusion of the thoracic aorta) injury is attenu-
ated in the heart of transgenic mice with cardiac-specific
TERT overexpression, and this correlated with reduced area
of MI, less fibrous area, and preservation of systolic
function.94,95
Based on the observations made in G5TERC-KO35 and
cardiac-specific TERT transgenic mice,94 and the demonstra-
tion that critically short telomeres in late-generation TERC-
null mice can become fully functional by telomerase restora-
tion,108 telomerase gene transfer may open new opportunities
for myocardial repair. However, potentially harmful effects
associated to telomerization must be considered, including
the following: (1) accelerated progression of atherosclerotic
plaques in CAD patients caused by homing of telomerized
cells into coronary vessels, because neovascularization is
enhanced by TERT overexpression88,89 and proliferation of
vasa vasorum promotes atherosclerosis83,84; and (2) develop-
ment of cardiac fibrosis and cancer as a result of indiscrim-
inate proliferation of telomerized cells within the heart.109,110
These potential risks could be attenuated by grafting cells
engineered to conditionally overexpress TERT in a temporal
and cardiac-restricted manner. An alternative approach may
be the use of telomerase-competent CSCs, which can be
isolated and ex vivo expanded and are capable of homing to
the injured myocardium of experimental animals when in-
jected either intravenously102 or directly into the ischemic
heart.101
Telomeres and Factors Affecting
Cardiovascular Risk
This section discusses in vitro and in vivo findings that have
established links between telomere homeostasis and factors
influencing CVD development (Table 2).
Estrogens
The lower incidence of CVD in premenopausal women
compared with men may be attributable, at least in part, to
estrogens.111–114 In addition to the well-characterized actions
on lipoprotein metabolism and on vascular cells, the influence
of estrogen on telomere homeostasis may also contribute to
their beneficial effects on the cardiovascular system. Both
human and animal studies have revealed higher telomerase
activity and diminished rate of age-related telomere ablation
resulting in longer telomeres in females than in males.8,9,24,26–28
Estrogen may indirectly exert a protective effect on telomeres
because of its antioxidant properties.115 Moreover, evidences
for direct effects of estrogens on telomerase activity have
been provided both in vitro and in vivo. First, telomerase
activity in the endometrium varies across the menstrual
cycle.116 Endometrial telomerase activity is negligible during
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menstruation but increases during the follicular phase,
reaches maximum levels immediately before ovulation, co-
inciding with a peak in estrogen levels and proliferative
activity, and then falls during the luteal phase. Of note,
postmenopausal endometrium and endometrium from women
treated with antiestrogens exhibit decreased telomerase activ-
ity. Second, estrogens induce TERT transcription in MCF-7
cells via an estrogen response element within the TERT
promoter,117 and activate in human ECs the phosphatidylino-
sitol 3-kinase/Akt pathway,118 which in turn enhances human
telomerase activity through hTERT phosphorylation.119
Raloxifene, a selective estrogen receptor modulator, also
upregulates telomerase activity in human umbilical ECs
(HUVECs).120 In accordance with these findings, Imanishi et
al found that estrogen reduces EPC senescence by increasing
TERT levels in a phosphatidylinositol 3-kinase/Akt-
dependent manner.121 Furthermore, estrogen stimulates in
vascular ECs the production of nitric oxide,118 which also
induces telomerase activity and delays EC senescence.122
Oxidative Stress
Accumulation of oxidative damage is thought to play an
important role in aging and associated diseases,123 including
CVD.124,125 Reactive oxygen species (ROS) regulate endo-
thelium-dependent vasodilation and VSMC growth, differen-
tiation, and apoptosis. Furthermore, lipid peroxidation and
protein nitration induced by some ROS are early events in the
atherosclerotic process. In recent years, an increasing body of
evidence has implicated oxidative damage in telomere dys-
function in vascular cells. Hydrogen peroxide and oxidized
low-density lipoproteins inhibit EC telomerase activity.126
Similarly, long-term exposure of HUVECs to mild oxidative
stress induced by perturbation of the glutathione redox cycle
resulted in accelerated downregulation of telomerase activity,
enhanced telomere erosion, and the premature onset of
replicative senescence.127 Consistent with these findings,
maximum levels of glutathione in proliferating 3T3 fibro-
blasts coincided with a peak of telomerase activity, and
glutathione depletion and restoration decreased and restored,
respectively, telomerase activity in these cells.128 Homocys-
teine, a cardiovascular risk factor whose atherogenic effects
have been ascribed to increased hydrogen peroxide produc-
tion,129 also increased the rate of telomere shortening in ECs,
and this effect was attenuated in a dose-dependent manner by
catalase treatment.130 On the other hand, prolonged oxidative
damage also inhibited telomerase activity and accelerated
telomere shortening in VSMCs,62 an effect that may be
mediated by the formation of 8-oxodG at the GGG triplet in
telomeric DNA.131 Recently, Demissie et al reported that
systemic oxidative stress assessed by urinary 8-epi-prosta-
glandin F2 is associated with shorter WBC telomere length in
hypertensive men from the Framingham Heart Study.132
The aforementioned studies are consistent with the notion
that oxidative stress inhibits telomerase activity and promotes
telomere exhaustion. Consistent with this view, several anti-
oxidants attenuate telomere shortening. ROS scavenging by
Asc2P, an oxidation-resistant derivative of vitamin C, slows
down telomere shortening and expands the lifespan of
HUVECs.133 Likewise, Haendeler et al134 demonstrated that
reduction of intracellular reactive oxygen species formation
by treatment of ECs with the antioxidant N-acetylcysteine
delays the loss of telomerase activity and the onset of
age-related replicative senescence, and inhibits the nuclear
export of TERT protein, a mechanism by which oxidative
stress may inhibit telomerase activity via Src kinase family–
dependent phosphorylation of hTERT at tyrosine 707.135
Aspirin, which possesses antioxidant properties,136,137 also
prevents the increase in ROS formation and telomerase
downregulation occurring during endothelial senescence.138
Hypertension
A major factor contributing to CVD in the elderly is hyper-
tension.46 Figure 5 summarizes animal and human studies that
TABLE 2. Human Studies Reporting Associations Between Factors Affecting Cardiovascular Risk and Telomere Length or
Telomerase Activity
Cardiovascular Risk Modulator Main Findings References
Gender Women display higher telomeres compared with men in WBCs from adult individuals 24, 26, 28
Oxidative stress Systemic oxidative stress is associated with shorter WBC telomere length in
hypertensive men
132
Oxidative damage correlates negatively with monocyte telomere length in type 2
diabetic patients
142
Hypertension WBC telomere length is inversely correlated with pulse pressure and hypertension 24, 28
Type 1 diabetes mellitus WBCs of patients with type 1 diabetes have significantly shorter telomeres than those
of nondiabetic control subjects
140
Type 2 diabetes mellitus, insulin
resistance, and obesity
Leukocytes from type 2 diabetic patients have significantly shorter telomeres than
those of nondiabetic subjects
141, 142
Insulin resistance and obesity correlate with enhanced telomere attrition rate in WBCs 29
Insulin resistance is inversely correlated with leukocyte telomere length 132
Obesity is inversely correlated with WBC telomere length in women 147
Smoking WBCs from smoking women have shorter telomere length 147
Sex- and age-adjusted WBC telomere length is lower in smokers than in nonsmokers 26
Psychological stress Psychological stress is significantly associated to higher oxidative stress, lower
telomerase activity, and shorter telomere length in WBCs
145
1174 Circulation Research November 24, 2006
 by on June 16, 2011 circres.ahajournals.orgDownloaded from 
have linked telomerase and telomere alterations to hyperten-
sion. Cao et al reported that both TERT expression and
telomerase activity are induced in the aorta, but not in other
tissues, of spontaneously hypertensive rats (SHR).63 These
changes occurred before the onset of hypertension, and were
accompanied by telomere lengthening and increased prolif-
eration of medial VSMCs. TERT downregulation by anti-
sense RNA inhibited proliferation and increased apoptosis of
cultured VSMCs, a response that was abrogated by ectopi-
cally overexpressed p53. Although these findings suggest that
early telomerase activation in aortic medial VSMCs may
contribute to the initial phases of vascular remodeling asso-
ciated to hypertension, Perez-Rivero et al recently found that
TERC-deficient mice develop hypertension.38 This pheno-
type was associated with higher blood and urinary levels of
the endothelium-derived vasoconstrictor peptide endothelin-1
(ET-1). Because no differences in the expression of the
precursor pre-pro-ET-1 were detected in aorta and renal
cortex of TERC-null mice, Perez-Rivero et al postulated that
increased levels of circulating ET-1 may be attributable to
increased expression of the endothelin-converting enzyme
(ECE-1), which converts pre-pro-ET-1 into biologically ac-
tive ET-1. In fact, ECE-1 mRNA expression was significantly
higher in TERC-deficient mice than in wild-type counter-
parts, and ECE-1 promoter activity was increased in TERC-
deficient murine embryonic fibroblasts (MEFs). These cells
also displayed enhanced production of ROS and their treatment
with antioxidants, such as catalase and N-acetylcysteine, reduced
ECE-1 promoter activity, thus suggesting a causal link between
ROS synthesis and ET-1 levels. Given these findings, the
authors hypothesized that telomerase deficiency and telomere
shortening may modify the phenotypic characteristics of vascu-
lar cells in a way that favors development of hypertension (eg,
increasing ET-1 production). Accordingly, EPCs from hyperten-
sive patients and from SHR and deoxycorticosterone acetate
(DOCA)-salt rats undergo accelerated senescence concomitantly
with lowered telomerase activity.139
Several studies have examined the potential relationship
between telomere length and human hypertension. By ana-
lyzing WBC telomere length in 49 twin pairs that included 38
men and 60 women 18 to 44 years of age, Jeanclos et al found
that telomere restriction fragment length correlated nega-
tively with systolic blood pressure but positively with dia-
stolic blood pressure, thus suggesting a negative relation
between telomere length and pulse pressure.24 Both pulse
pressure and telomere length appeared highly heritable and
the correlation between these parameters was sex indepen-
dent. In another study that included 120 men and 73 women
(mean age: 5611 years) who were not taking any antihy-
pertensive medication, Benetos et al found a negative corre-
lation between telomere length and age in both sexes, but
telomere shortening significantly contributed to increased
pulse pressure and pulse wave velocity only in men.28 Both
studies found age-adjusted longer telomeres in women, pos-
sibly as a consequence of the beneficial effects of estrogens
on telomere homeostasis (see above). More recently, Demis-
sie et al confirmed the association between shorter leukocyte
telomere length and hypertension in 327 men from the
Framingham Heart study and suggested that increased telo-
mere ablation in hypertensives was largely attributable to
insulin resistance.132
Diabetes
Diabetic patients are at higher risk for microvascular and
macrovascular disease.45 Jeanclos et al reported that telomere
length in WBCs from patients with type 1 diabetes, an
autoimmune disease in which subsets of immune cells are
involved in the destruction of pancreatic  cells, is reduced
compared with age-matched nondiabetic controls.140 Because
this parameter was undistinguishable when comparing type 2
diabetic patients and nondiabetic controls, the authors sug-
gested that telomere shortening occurs in subsets of WBCs
that play a role in the pathogenesis of type 1 diabetes.
However, recent reports have shown that shorter telomeres
are also associated to insulin resistance and to type 2
diabetes.29,132,141–143 Notably, Gardner et al found that insulin
resistance and obesity correlate with an enhanced rate of
telomere attrition, which may be caused by heightened
oxidative stress or inflammation occurring in these
conditions.29
Psychological Stress and Smoking
It is generally accepted that psychological stress leads to
accelerated aging and the premature onset of age-related
disease. Chronic stress has been linked to increased cardio-
vascular risk,144 although the underlying mechanisms remain
Figure 5. Associations among hyperten-
sion, telomerase, and telomere length in
different tissues and cell types from
humans and experimental animals. Ref-
erence nos. are shown.
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largely unknown. Of note in this regard, chronic psycholog-
ical stress correlated with higher oxidative stress and shorter
telomere length in WBCs from healthy premenopausal
women.145
Cigarette smoking is another important cardiovascular
risk factor related to augmented oxidative stress.146 By
examining a random sample of Belgian families from the
cohort of the Flemish Study on Environment, Genes and
Health Outcomes, Nawrot et al found shorter telomeres in
WBCs from smokers compared with nonsmokers after
adjusting for sex and age.26 More recently, Valdes et al
confirmed that WBCs from smoking women have shorter
telomeres and suggested that smoking reduces WBC telo-
mere length in a dose-dependent manner.147 However, it
has been reported that a history of smoking, assessed either
in terms of smoking status or pack years, has no indepen-
dent effects on mean telomere restriction fragment length
in WBCs73 and that WBC telomere attrition is not corre-
lated with smoking in individuals 70 years of age.70,75
Conclusions and Future Perspectives
The following findings have conclusively linked telomere
biology and CVD: (1) Like in other cell types, gain- and
loss-of-function experiments demonstrate that telomerase and
functional telomeres are necessary for maintaining the pro-
liferative potential and viability of cultured ECs, VSMCs and
cardiomyocytes; (2) short telomeres have been detected in
senescent ECs and VSMCs from human atherosclerotic
plaque, in myocardial tissue from patients with end-stage
heart failure and cardiac hypertrophy, as well as in WBCs
from patients with CAD, premature MI, hypertension, and
diabetes mellitus, although some controversy among different
epidemiologic studies exist; (3) TERC-null mice with criti-
cally short telomeres develop hypertension, ventricular dila-
tion, thinning of myocardium, cardiac dysfunction, and sud-
den death; in contrast, heart damage induced by mechanical
injury and ischemia is reduced in transgenic mice with
cardiac-specific expression of TERT, which maintain telo-
mere length in adult myocardium.
A chief question that remains unanswered is whether
telomere exhaustion is cause or consequence of CVD.
Given that an accelerated rate of telomere shortening may
be expected from the increased cellular turnover associated
to inflammation occurring in atherosclerosis, and from the
action of several cardiovascular risk factors (eg, oxidative
stress, hypertension, diabetes, smoking, psychological
stress), telomere exhaustion may be a surrogate marker of
CVD. However, it is tempting to speculate that short
telomere length at birth, which seems to be mostly genet-
ically determined, predisposes to atherosclerosis and asso-
ciated CVD, in part as a result of premature senescence of
leukocytes, vascular cells, and cardiac myocytes. Contrary
to this notion, hypercholesterolemic mice doubly deficient
in apoE and TERC had shorter telomeres, exhibited a
marked reduction in leukocyte proliferation, and were
protected from atherosclerosis compared with apoE-null
mice with an intact TERC gene. Thus, although telomer-
ization strategies aimed at maintaining/restoring telomere
length may prevent or ameliorate endothelial senescence/
dysfunction and improve neovascularization of ischemic
territories, such an approach may accelerate atheroma
progression by aggravating neointimal leukocyte and
VSMC proliferation. On the other hand, it remains unex-
plored whether alterations in telomere length affect throm-
bus formation, a frequent cause of MI and stroke in
patients with atherosclerotic disease.
Another field of interest is the possible application of
telomerase in tissue engineering, for instance in the genera-
tion of artificial blood vessels and in cell-based myocardial
regeneration. The use of autologous donor cells for these
purposes is often not viable because of their limited replica-
tive lifespan, particularly when they are obtained from elderly
patients, an obstacle that may be circumvented by telomerase
gene transfer. However, concern exists regarding the safety of
this approach. Specifically, telomerization may aggravate
atherosclerosis by promoting vessel neovascularization.
Moreover, because telomerase endow normal cells with
unlimited proliferative potential and is reactivated in most
human tumors, indiscriminate telomere lengthening within
the heart may provoke fibrosis and cancer. Of note in this
regard, hTERT overexpression in VSMCs from elderly pa-
tients does not lead to a transformed phenotype at population
doubling 100.148 The potential side effects of telomerase
gene transfer could be limited by either using donor cells with
conditional hTERT overexpression or telomerase-competent
CSCs.
In conclusion, more basic research and large epidemio-
logical studies are needed to conclusively ascertain
whether telomere erosion is an independent cardiovascular
risk factor or a consequence of CVD and to examine the
efficacy of novel therapeutic strategies aimed at modifying
telomere length. The generation of genetically engineered
mice exhibiting tissue-specific alterations in telomerase
and additional telomere-associated proteins with possible
roles in the pathogenesis of CVD remains unexplored and
would be an invaluable tool to answer these questions.
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